FDA Peptide Reclassification 2026: What Researchers Want Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # FDA to Convene Pharmacy Compounding Advisory Committee in July The Sikiric Problem: One Lab, Thirty Years, Zero Trials That Matter FDA Evaluates Peptides for Section 503A Compounding List Lance Liberti, MBA, BCPA posted on the topic LinkedIn